You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

Filter Results

Select search scope: search across all journals or within the current journal

Search this journal

Enter search terms…

Advanced search

Browse

About

About Sage
About Sage Journals
Privacy Policy
Terms of Use
Contact Us
Help

Information for

Authors
Editors
Librarians
Researchers
Reviewers
Frequently asked questions

All content on this site: Copyright © 2026 Sage Publications. All rights reserved. This website is technically supported and operated by China National Publications Import and Export (Group) Co., Ltd. 京ICP备09090397号-11

Reply: Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment

Annals of Pharmacotherapy

Impact Factor: 2.3 / 5-Year Impact Factor: 2.7

Journal Homepage Submission guidelines

Restricted access

Letter

First published online July, 2021

Reply: Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment

, , and

Volume 55, Issue 7

https://doi.org/10.1177/1060028020973607

Abstract

Get full access to this article

View all access options for this article.

References

Mullins

Beaulac

Sylvia

. Drug-induced liver injury (DILI) with micafungin: the importance of causality assessment. Ann Pharmacother. 2020;54:526-532. doi:10.1177/1060028019892587

Bracken

Nunn

Kirkham

, et al. Development of the Liverpool adverse drug reaction avoidability assessment tool. PLoS One. 2017;12:e0169393. doi:10.1371/journal.pone.0169393

Browse journal

Current issue OnlineFirst All issues

Similar articles

Available access

Degeneration and Dysfunction of Retinal Neurons in Acute Ocular Hypertensive Rats: Involvement of Calpains

Available access

i Drugs and i Devices Discovery Research: Preclinical Assays,Techniques,and Animal Model Studies for Ocular Hypotensives and Neuroprotectants

Available access

Eyes on New Product Development

Available access

The Effects of Commercially Available Preservative-Free FDA-Approved Triamcinolone (Triesence ® ) on Retinal Cells in Culture